10104637Leveraging biomimicry and evidence-based medicine to treat patients with chronic woundsClosedEU-FundedHorizon Europe GuaranteeAccess to and delivery of affordable wound care are significant challenges to chronic wound patients. Globally, over 40 million people suffer from chronic wounds, and the economic burden of chronic wound treatment exceeds €100 billion annually. 1-2% of the populations of developed countries will experience a chronic wound in their lifetime. Chronic wounds can severely diminish a person’s quality of life. Current treatment solutions are inadequate. Responding to this need, SolasCure is developing an investigational product, Aurase Wound Gel, a hydrogel containing a highly-specific enzyme, isolated and cloned from medical maggots. The medical use of Aurase Wound Gel aims to lead to faster wound cleaning, a precondition to healing - promoting better patient outcomes and reduced healthcare costs. With the help of EIC, SolasCure aims to conduct Clinical Phase 2b trials and to establish a dry formulation of Aurase Wound Gel & its optimisation.